Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | SCN4A | P35499 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27721990 | 1.00 | GBA1 (0.49) | GBA1SCN4ASRCALDH1A1CYP2C19 | |
| SCHEMBL8526440 | 0.83 | GBA1 (0.52) | GBA1SCN4ADPP4F2 | |
| SCHEMBL17287844 | 0.83 | GBA1 (0.52) | GBA1SCN4ADPP4F2 | |
| SCHEMBL6422777 | 0.81 | PTGS1 (0.50) | SCN4AALDH1A1 | |
| SCHEMBL2935549 | 0.80 | SRC (0.48) | GBA1SRCALDH1A1CYP2C19 | |
| SCHEMBL27700349 | 0.80 | TACR1 (0.43) | GBA1SRCALDH1A1CYP2C19DPP4 | |
| SCHEMBL6034394 | 0.80 | GABBR2 (0.42) | GBA1DPP4F2 | |
| SCHEMBL6032624 | 0.80 | GABBR2 (0.64) | SCN4ACYP2C19 | |
| SCHEMBL6033113 | 0.80 | GABBR2 (0.42) | DPP4F2 | |
| SCHEMBL6033150 | 0.80 | GABBR2 (0.42) | GBA1ALDH1A1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0467856-B1 | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | claimed |
| EP-0467856-A2 | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1992-01-22 | — | — | EP | claimed |
| CN-101851182-B | Salt-free preparation method for substituted taurine | UNIV BEIJING CHEMICAL | 2013-07-17 | — | — | CN | disclosed |
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2012-02-02 | — | — | US | disclosed |
| EP-2376444-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | The Royal College of Surgeons in Ireland (IE) | 2011-10-19 | — | — | EP | disclosed |
| CN-101148427-B | Method for preparing substituted taurine | UNIV BEIJING | 2010-10-27 | — | — | CN | disclosed |
| CN-101851182-A | Salt-free preparation method for substituted taurine | UNIV BEIJING CHEMICAL | 2010-10-06 | — | — | CN | disclosed |
| WO-2010066450-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066450-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196456-A1 | A method for preparing sulfur-containing compounds | Royal College of Surgeons in Ireland (IE) | 2010-06-16 | — | — | EP | disclosed |
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000406-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-01-06 | — | — | WO | disclosed |
| EP-0467856-B1 | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | disclosed |
| CN-1125440-A | Fiber reactive anthraquinone dyes | HOECHST CELANESE CORP (US) | 1996-06-26 | — | — | CN | disclosed |
| EP-0467856-A2 | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4617382-A | PRINTING; DYEING; SILK, LEATHER, WOOL AND POLYAMIDES | CIBA-GEIGY CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |
| US-4219473-A | Substituted unsymmetrical azo, azomethine 1:2 chromium complexes | CIBA-GEIGY CORPORATION (US) | 1980-08-26 | — | — | US | disclosed |
| US-4053462-A | UNSYMMETRICAL PHENYL AZO NAPHTHYL CHROMIUM COMPLEX DYES | CIBA-GEIGY CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-4005065-A | GOOD FASTNESS TO LIGHT, PERSPIRATION, FULLING, DECATIZING AND CARBONIZING | CIBA-GEIGY CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | SULT1E1, SULT1A1, TST | GBA1 1854/4885SCN4A 362/4885SRC 937/4885 |
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | APP, PSEN1, PSEN2 | GBA1 21/4885SCN4A 128/4885SRC 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.